|Dr. Ron Cohen||Founder, CEO, Pres & Director||1.5M||N/A||1956|
|Ms. Lauren M. Sabella||Chief Commercial Officer||758.61k||N/A||1961|
|Dr. Burkhard Blank||Chief Medical Officer and Head of R&D||860.59k||N/A||1955|
|Mr. Robert Morales||Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller||N/A||N/A||1967|
|Ms. Felicia Vonella||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Andrew Mayer J.D.||Sr. VP, Deputy Gen. Counsel & Corp. Sec.||N/A||N/A||N/A|
|Ms. Tierney Saccavino||Exec. VP of Corp. Communications||N/A||N/A||N/A|
|Ms. Denise J. Duca||Exec. VP of HR||N/A||N/A||N/A|
|Dr. Andrew R. Blight||Chief Scientific Officer Emeritus||N/A||N/A||1951|
|Mr. Peter S. Carbone||Exec. VP of Quality||N/A||N/A||N/A|
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Acorda Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 6. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 8; Compensation: 6.